Insight into the Effect of Tenofovir in Patients with HBV/HIV Coinfection

Prior 3TC use, a higher baseline hepatitis B virus DNA level, and a lower nadir CD4 count were associated with decreased response to tenofovir.

Hepatitis B virus (HBV) coinfection is common in HIV-infected patients. Current HBV therapies suppress HBV replication and can improve clinical outcomes but are rarely curative, so long-term treatment is needed. Most antiretroviral therapy (ART) regimens include two or three drugs with HBV activity (3TC, FTC, tenofovir), yet we have comparatively few data on HBV outcomes among patients on long-term ART. This issue is important, particularly because using 3TC or FTC alone for targeting HBV in coinfected patients often leads to development of HBV resistance. In a recent study involving HBV/HIV-coinfected CNICS-cohort patients who were taking a tenofovir-based regimen for ≥3 months and had on-treatment HBV DNA measurements, researchers examine…

Reviewing Author

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Keith Henry, MD

Disclosures

Consultant/Advisory BoardViiV Advisory Board

Editorial BoardsJAIDS: Journal of Acquired Immune Deficiency Syndromes

Insight into the Effect of Tenofovir in Patients with HBV/HIV Coinfection

Topics

Reviewing Author